RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Lee’s Pharm, a China in-licensing company, announced a $22.5 million agreement for China and Southeast Asia rights to a preclinical cardioprotective molecule developed by Auransa of Palo Alto, CA. Auransa uses its SMarTR™ Engine AI-driven platform to discover non-obvious drug candidates. AU018 is intended to be administered along with doxorubicin to mitigate the cardiotoxicity side effect of the chemotherapy. In early testing, AU018 did not interfere with doxorubicin’s activity.
Source: China Biotoday
